Meningococcal B vaccination (4CMenB) in infants and toddlers

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Neisseria meningitidis is a Gram-negative pathogen that actively invades its human host and leads to the development of life-threatening pathologies. One of the leading causes of death in the world, N. meningitidis can be responsible for nearly 1,000 new infections per 100,000 subjects during an epidemic period. The bacterial species are classified into 12 serogroups, five of which (A, B, C, W, and Y) cause the majority of meningitides. The three purified protein conjugate vaccines currently available target serogroups A, C, W, and Y. Serogroup B has long been a challenge but the discovery of the complete genome sequence of an MenB strain has allowed the development of a specific four-component vaccine (4CMenB). This review describes the pathogenetic role of N. meningitidis and the recent literature concerning the new meningococcal vaccine.

Original languageEnglish
Article number402381
JournalJournal of Immunology Research
Volume2015
DOIs
Publication statusPublished - 2015

Fingerprint

Neisseria meningitidis
Vaccination
Meningococcal Vaccines
Conjugate Vaccines
Meningitis
Cause of Death
Genome
Pathology
Infection
Serogroup
Proteins

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Meningococcal B vaccination (4CMenB) in infants and toddlers. / Esposito, Susanna; Tagliabue, Claudia; Bosis, Samantha.

In: Journal of Immunology Research, Vol. 2015, 402381, 2015.

Research output: Contribution to journalArticle

@article{f8b4476866d945eca92e324728abe4b9,
title = "Meningococcal B vaccination (4CMenB) in infants and toddlers",
abstract = "Neisseria meningitidis is a Gram-negative pathogen that actively invades its human host and leads to the development of life-threatening pathologies. One of the leading causes of death in the world, N. meningitidis can be responsible for nearly 1,000 new infections per 100,000 subjects during an epidemic period. The bacterial species are classified into 12 serogroups, five of which (A, B, C, W, and Y) cause the majority of meningitides. The three purified protein conjugate vaccines currently available target serogroups A, C, W, and Y. Serogroup B has long been a challenge but the discovery of the complete genome sequence of an MenB strain has allowed the development of a specific four-component vaccine (4CMenB). This review describes the pathogenetic role of N. meningitidis and the recent literature concerning the new meningococcal vaccine.",
author = "Susanna Esposito and Claudia Tagliabue and Samantha Bosis",
year = "2015",
doi = "10.1155/2015/402381",
language = "English",
volume = "2015",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Limited",

}

TY - JOUR

T1 - Meningococcal B vaccination (4CMenB) in infants and toddlers

AU - Esposito, Susanna

AU - Tagliabue, Claudia

AU - Bosis, Samantha

PY - 2015

Y1 - 2015

N2 - Neisseria meningitidis is a Gram-negative pathogen that actively invades its human host and leads to the development of life-threatening pathologies. One of the leading causes of death in the world, N. meningitidis can be responsible for nearly 1,000 new infections per 100,000 subjects during an epidemic period. The bacterial species are classified into 12 serogroups, five of which (A, B, C, W, and Y) cause the majority of meningitides. The three purified protein conjugate vaccines currently available target serogroups A, C, W, and Y. Serogroup B has long been a challenge but the discovery of the complete genome sequence of an MenB strain has allowed the development of a specific four-component vaccine (4CMenB). This review describes the pathogenetic role of N. meningitidis and the recent literature concerning the new meningococcal vaccine.

AB - Neisseria meningitidis is a Gram-negative pathogen that actively invades its human host and leads to the development of life-threatening pathologies. One of the leading causes of death in the world, N. meningitidis can be responsible for nearly 1,000 new infections per 100,000 subjects during an epidemic period. The bacterial species are classified into 12 serogroups, five of which (A, B, C, W, and Y) cause the majority of meningitides. The three purified protein conjugate vaccines currently available target serogroups A, C, W, and Y. Serogroup B has long been a challenge but the discovery of the complete genome sequence of an MenB strain has allowed the development of a specific four-component vaccine (4CMenB). This review describes the pathogenetic role of N. meningitidis and the recent literature concerning the new meningococcal vaccine.

UR - http://www.scopus.com/inward/record.url?scp=84940842199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940842199&partnerID=8YFLogxK

U2 - 10.1155/2015/402381

DO - 10.1155/2015/402381

M3 - Article

AN - SCOPUS:84940842199

VL - 2015

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

M1 - 402381

ER -